ACRV – acrivon therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its price target lowered by analysts at BMO Capital Markets from $28.00 to $27.00. They now have an "outperform" rating on the stock.
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Miller Mary
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Peterson Katharine
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Holm-Jorgensen Rasmus
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Gamelin Erick
Form 4 Acrivon Therapeutics, For: Nov 14 Filed by: Devroe Eric
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.